Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 3, 2010, Pages 151-159

  Kolbe, Karin ^a   Karstens, Astrid ^a   Krämer, Irene ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

capsule formulation; high dose busulfan; HPLC analysis; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAPSULE ENDOSCOPE; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; STEADY STATE; STEM CELL TRANSPLANTATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ALKYLATING AGENTS; AREA UNDER CURVE; BUSULFAN; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TRANSPLANTATION CONDITIONING;

EID: 77956255679     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209340487     Document Type: Article

References (27)

1. Pawlowska AB, Blazar BR, Angelucci E., Baronciani D., Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997 ; 20: 915-920.
2. Bostrom B., Enockson K., Johnson A., Bruns A., Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediat Transplant 2003 ; 7 (Suppl. 3). 12-18.
3. Bleyzac N., Souillet G., Magron P., Janoly A., Martin P., Bertrand Y. et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001 ; 28: 743-751.
4. Dix SP, Wingard JR, Mullins RE, Jerkunica I., Davidson TG, Gilmore C. et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996 ; 17: 225-230.
5. Vassal G., Fischer A., Challine D., Boland I., Ledheist F., Lemerle S. et al. Busulfan disposition below the age of three: Alteration on children with lysosomal storage disease. Blood 1993 ; 82: 1030-1034.
6. Hassan M., ödberg G., Ehrsson H., Ehrnebo M., Wallin B., Töttermann T. et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989 ; 36: 525-530.
7. Vassal G., Gouyette A., Hartmann O., Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989 ; 24: 386-390.
8. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000 ; 95: 1188-1194.
9. Deeg HJ, Storer B., Slattery JT, Anasetti C., Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002 ; 100: 1201-1207.
10. Witherspoon RP, Deeg HJ, Storer B., Anasetti C., Storb R., Appelbaum FR Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001 ; 19: 2134-2141.
11. Grochow LB Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993 ; 20: 18-25.
12. Slattery JT, Clift RA, Buckner CD, Radich J., Sorer B., Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997 ; 89: 3055-3060.
13. McCune JS, Gooley T., Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002 ; 30: 167-173.
14. Radich JP, Gooley T., Bensinger W., Chauncey T., Clift R., Flowers M. et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003 ; 102: 31-35.
15. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001 ; 28: 1013-1018.
16. Hassan M., Nilsson C., Hassan Z., Gungor T., Aschan J., Winiarski J. et al. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m2 as a optimal total dose for conditioning. Bone Marrow Transplant 2002 ; 30: 833-841.
17. Hassan Z., Ljungman P., Ringdén O., Winiarski J., Nilsson C., Aschan J. et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001 ; 27: 479-485.
18. Olavarria E., Hassan M., Eades A., Nilson C., Timms A., Matthews J. et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000 ; 14: 1954-1959.
19. Schuler US, Ehrsam M., Schneider A., Schmidt H., Deeg J., Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant 1998 ; 22: 241-244.
20. Grochow LB Parenteral busulfan: is therapeutic monitoring still warranted? Biol Blood Marrow Transplant 2002 ; 8: 465-457.
21. Vassal G., Michel G., Espérou H., Gentet JC, Valteau-Couanet D., Doz F. et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008 ; 61: 113-123.
22. Bleyzac N., Barou P., Aulagner G. Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B 2000 ; 742: 427-432.
23. Shaw PJ, Scharping CE, Brian RJ, Earl JW Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994 ; 84: 2357-2362.
24. Schuler U., Schroer A., Kühnle A., Blanz J., Mewes K., Kumbier I. et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted. Bone Marrow Transplant 1994 ; 14: 759-765.
25. Hassan M., ödberg G., Ehrsson H., Ehrnebo M., Wallin B., Smedmyr B. et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989 ; 36: 525-530.
26. McCune JS, Gibbs JP, Slattery JT Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000 ; 39: 155-165.
27. Slattery JT, Risler LJ Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998 ; 20: 543-549.